# Nilotinib in the Treatment of Systemic Sclerosis

> **NCT01166139** · PHASE2 · COMPLETED · sponsor: **Hospital for Special Surgery, New York** · enrollment: 10 (actual)

## Conditions studied

- Systemic Sclerosis

## Interventions

- **DRUG:** Nilotinib (Tasigna)

## Key facts

- **NCT ID:** NCT01166139
- **Lead sponsor:** Hospital for Special Surgery, New York
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-07
- **Primary completion:** 2014-07
- **Final completion:** 2015-01
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2017-10-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01166139

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01166139, "Nilotinib in the Treatment of Systemic Sclerosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01166139. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*